- In
clinical trials,
reactogenicity is the
capacity of a
vaccine to
produce common, "expected"
adverse reactions,
especially excessive immunological responses...
-
attenuated whole cells or
lysates have been
replaced largely by less
reactogenic, cell-free
vaccines consisting of
purified components,
including capsular...
- on 8
August 2021.
Retrieved 17
January 2021. "Study of the Safety,
Reactogenicity and
Immunogenicity of "EpiVacCorona"
Vaccine for the
Prevention of COVID-19...
-
currently used
anthrax vaccines show
considerable local and
general reactogenicity (erythema, induration, soreness, fever) and
serious adverse reactions...
-
Diseases (NIAID) (1 June 2018), A
Phase I
Trial to
Evaluate the Safety,
Reactogenicity, and
Immunogenicity of MVA-BN
Yellow Fever Vaccine With and Without...
- Rec-Biotechnology Co Ltd.
Clinical trial number NCT04818801 for "Safety,
Reactogenicity and
Immunogenicity Study of ReCOV" at ClinicalTrials.gov
Clinical trial...
- gov
Clinical trial number NCT04732871 for "Immunogenicity, Safety,
Reactogenicity and
Persistence of an
Investigational Respiratory Syncytial Virus (RSV)...
-
Using a single-injection
vaccine has
shown to not
cause any
adverse reactogenicity,
which the
possible immune response to vaccination, in
comparison to...
-
Clinical trial number NCT01160172 for "A
Study to
Evaluate the Safety,
Reactogenicity and
Immunogenicity of GSK Biologicals'
Staphylococcal Investigational...
-
Biotech Co., Ltd. It was
found to be safe and well tolerated. "Safety,
Reactogenicity, and
Immunogenicity of a
Recombinant SARS-CoV-2
Vaccine LYB001 in healthy...
